{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-012346","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2026-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.881843+00:00","generated_at":"2026-05-15T08:07:43.972896+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Femasys reports 2025 revenue up 40.8% to $2.3M; net loss $18.6M; cash into Q3 2026","bullets":["Revenue increased 40.8% to $2,293,313 in 2025 from $1,629,108 in 2024, driven by FemBloc sales.","Net loss was $18,627,887 ($0.47 per share) vs $18,816,628 ($0.85 per share) in 2024; EPS improved on share count increase.","Cash and cash equivalents $9.3M as of Dec 31, 2025; expects to fund operations into Q3 2026.","Initiated patient enrollment in FINALE pivotal trial for FemBloc; received MDSAP certification.","Completed $12M financing in late 2025; appointed Kenneth D. Eichenbaum to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-012346","json":"https://secwatch.observer/filing/0001140361-26-012346.json","markdown":"https://secwatch.observer/filing/0001140361-26-012346.md","text":"https://secwatch.observer/filing/0001140361-26-012346.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036126012346/0001140361-26-012346-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036126012346/ef20069346_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:07:43.972896+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"06d43ecf2381ab8741c2c131a73733af6335332b","claim":"FEMASYS INC reported year ended December 31, 2025 results: revenue $2,293,313, net income $18,627,887, EPS ($0.47).","evidence_excerpt":"critical gaps with innovative, safe, and technologically advanced solutions.” Financial Results for Year Ended December 31, 2025 • Sales increased by $664,205, or 40.8%, to $2,293,313 in 2025 from $1,629,108 in 2024, primarily due to sales of FemBloc. • Research and development expenses decreased by $638,839, or 7.8%, to $7,577,704 in 2025 compared to","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1339005/000114036126012346/0001140361-26-012346-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"year ended December 31, 2025"},{"label":"Revenue","value":"$2,293,313"},{"label":"Net income","value":"$18,627,887"},{"label":"EPS","value":"($0.47)"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}